Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Novel therapies for children with severe asthma
Top Ten Searches
hla beta 2 probiotics hypo allergenic scid urticaria aeroallergens asthma angioedema hivYour Article Summary
See Latest ArticlesTarget-dependent T-cell Activation by Coligation With a PSMAxCD3 Diabody Induces Lysis of Prostate Cancer Cells
Journal of Immunotherapy, 06/24/09
Buhler P et al. - Although the diabody binds to all T-cells, only those in contact with PSMA-expressing cancer cells are activated. The PSMA×CD3 diabody is suitable for a controlled polyclonal T-cell therapy of prostate cancer.
Today in Hematology/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: Evaluation of efficacy and tolerance
Journal of Clinical Oncology, 10/23/09
Update of the guidelines for lupus anticoagulant detection
Journal of Thrombosis and Haemostasis, 09/28/09
Romiplostim in chronic immune thrombocytopenic purpura
Clinical Therapeutics, 10/23/09
Today in Nephrology/Urology...keeping you current
Receive free subspecialty "5-minute updates" via email
Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: Evaluation of efficacy and tolerance
Journal of Clinical Oncology, 10/23/09
Mycophenolate Mofetil Reduces Late Renal Allograft Loss Independent of Acute Rejection
Transplantation, 10/29/09
T Cell–Based Immunotherapy of Metastatic Renal Cell Carcinoma: Modest Success and Future Perspective
Clinical Cancer Research, 10/26/09
Sponsor
Article Search
Sponsor